Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a ...

Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. Tempus is a technology ...

Ambry Genetics will continue operations as a wholly ... section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics ...

Ambry, a 25-year-old genetics testing firm, is expected to generate over $300 million in revenue this year, with growth boosted by market share gains following Invitae’s bankruptcy.

On February 3 rd, the company announced that it had completed its acquisition of Ambry Genetics, a genetic testing company that strives to improve health by understanding the relationship between ...

In Q3 2024, Tempus announced its intent to acquire Ambry Genetics in a deal valued at 15x EBITDA at $600mm, $375mm of which through cash and the remaining $225mm in equity. Ambry will expand ...

They also inked cornerback Ambry Thomas to a reserve/futures contract after signing over a dozen players to such deals on Wednesday. The #Vikings have re-signed DL Jalen Redmond. pic.twitter.com ...

The Minnesota Vikings announced they have signed CB Ambry Thomas to a futures contract. The #Vikings have signed CB Ambry Thomas to a reserve/future free agent contract. — Minnesota Vikings ...